Markwell Clarizio LLP

Announcement of a new Canadian Drug Agency by the Government of Canada

On December 18, 2023, the Government of Canada announced the creation of the Canadian Drug Agency (“CDA”) built from CADTH in partnership with provinces and territories. The implementation of CDA is supported by an investment of $89.5 million over 5 years.   The creation of the CDA has been in the works for many years. […]

Announcement of a new Canadian Drug Agency by the Government of Canada Read More »

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part III

Co-written with Dino Clarizio This is the third of a series of three posts discussing some of the issues addressed by the trial judge (McVeigh J.) in NCS v Kobold, 2023 FC 1486. The three issues we discuss are those that arise less frequently in patent cases. They are: Topic 1: Priority Date (Post #1)Topic

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part III Read More »

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part II

Co-written with Dino Clarizio This is the second of a series of three posts discussing some of the issues addressed by the trial judge (McVeigh J.) in NCS v Kobold, 2023 FC 1486. The three issues we discuss are those that arise less frequently in patent cases. They are: Topic 1: Priority Dates (Post #1)Topic

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part II Read More »

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part I

Co-written with Dino Clarizio In a complex patent infringement action involving five NCS patents and one Kobold patent relating to tools and sleeves used in oil well drilling, the Federal Court (per McVeigh J.) held that NCS’s patents were invalid and not infringed, and that Kobold’s patent was valid and infringed by NCS. As a

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part I Read More »

FCA Reaffirms Strict Rules for Patent Lists Under the PMNOC Regulations

Federal Court of Appeal (Locke JA writing) holds that PMNOC Regulations do not allow a first person to amend an existing patent list to create a new patent linkage. Janssen Inc. v. Canada (Health) – Federal Court of Appeal (fca-caf.ca) Janssen Inc. v. Canada (Health) – Federal Court (fct-cf.gc.ca) This decision concerns the arcane timing

FCA Reaffirms Strict Rules for Patent Lists Under the PMNOC Regulations Read More »

Magnitude of Savings as a Factor on Bifurcation Motions

Federal Court (per McHaffie J.) dismisses motion to bifurcate a patent infringement action due to insufficient evidence. Bessette v. British Columbia – Federal Court (fct-cf.gc.ca) In Canada, the default process for patent infringement actions is that all issues are heard and decided together in a single trial. However, the Federal Court has a discretionary power

Magnitude of Savings as a Factor on Bifurcation Motions Read More »

Sandoz v. Janssen 2023 FCA 221: Threshold for Sound Prediction

The Federal Court of Appeal (Locke JA writing for the Court) recently confirmed the threshold for establishing a sound prediction of utility. Sandoz v Janssen 2023 FCA 221 Canadian patent law requires that, to prevent the filing of patent applications based on speculation, utility must be either demonstrated or the requirements for a sound prediction

Sandoz v. Janssen 2023 FCA 221: Threshold for Sound Prediction Read More »

Inducing Infringement with a Skinny Label: FCA Weighs-In

The Federal Court of Appeal (Locke JA writing for the Court) held that Apotex will induce infringement of patent claims to a combination of two active ingredients to treat a condition even though Apotex is seeking approval to market only one of the active ingredients as a monotherapy for the same condition. https://lnkd.in/gkb9faVi Janssen is the

Inducing Infringement with a Skinny Label: FCA Weighs-In Read More »

Angelcare v Munchkin: Entitlement to Infringement Remedies

Co-written with Dino Clarizio The Federal Court of Canada (per Roy J.) decided four issues of entitlement to remedies in an action where he had previously held that the defendants’ products sold in Canada infringed valid claims. The issues were 1) entitlement to injunctive relief; 2) entitlement to an accounting of profits; 3) entitlement to

Angelcare v Munchkin: Entitlement to Infringement Remedies Read More »